ALPHAMAB-B (09966) released its interim results, reporting a loss attributable to shareholders of 40.461 million yuan, turning from profit to loss year-on-year.

ALPHAMAB-B (09966) announced its interim results for the six months ended June 30, 2026, reporting revenue of 271 million yuan, a decrease of 15.09% year-on-year; a loss of 40.461 million yuan for the period, compared to a profit of 21.575 million yuan in the same period last year; and a loss per share of 0.04 yuan. The Group will continue to strive to provide world-class innovative therapeutic biopharmaceuticals for patients worldwide through our unique drug discovery and development capabilities. Leveraging our strong independent R&D capabilities and technology platform, we will identify, validate, and select leading candidate drugs to enrich our early pipeline, with a focus on ADCs. We will also continue to optimize manufacturing processes and technologies to improve product quality and reduce costs. To maximize the commercial value of our global patent assets, we will continue to actively seek more strategic collaboration opportunities, such as co-development, joint development partnerships, and external licensing.